London: Friday, April 29, 2016: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at April 29, 2016, the issued share capital of Chi-Med consisted of 60,639,926 ordinary shares of US$1.00 each, with each share carrying one right to vote and with no shares held in treasury.
The above figure of 60,639,926 may be used by shareholders as the denominator for the calculations by which they could determine if they are required to notify their interest in, or a change to their interest in, Chi-Med under the Financial Conduct Authority’s Disclosure Rules and Transparency Rules.
For illustrative purposes only, the 60,639,926 ordinary shares would be equivalent to 60,639,926 CREST depositary interests (each equating to one ordinary share) which are traded on AIM or, if the CREST depositary interests were converted in their entirety, equivalent to 121,279,852 American depositary shares (each equating to one-half of one ordinary share) which are traded on Nasdaq.
|
Investor Inquiries |
|
|
Christian Hogg, CEO |
+852 2121 8200 |
|
International Media Inquiries |
|
|
Anthony Carlisle, Citigate Dewe Rogerson |
+44 7973 611 888 (Mobile) |
|
U.S. Based Media Inquiries |
|
|
Brad Miles, BMC Communications |
+1 (917) 570 7340 (Mobile) |
|
Susan Duffy, BMC Communications |
+1 (917) 499 8887 (Mobile) |
|
Investor Relations |
|
|
Jillian Connell, The Trout Group |
+1 (646) 378 2956 |
|
David Dible, Citigate Dewe Rogerson |
+44 20 7638 9571 |
|
Panmure Gordon (UK) Limited |
|
|
Richard Gray / Andrew Potts |
+44 (20) 7886 2500 |
Chi-Med is a China-based, globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.
London: Wednesday, April 27, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that all ordinary resolutions and the special resolution put to its Annual General Meeting (“AGM”) held on April 27, 2016 were duly passed. The poll results of the resolutions were as follows:
|
|
|
Number of Votes (%)* |
|||||||
|
Resolutions |
|
For |
|
Against |
|
Withheld# |
|||
|
|
|
|
|
|
|
|
|||
|
1 |
To consider and adopt the statement of audited accounts and the reports of the directors and independent auditor for the year ended December 31, 2015. |
|
50,155,497 |
|
280 |
|
21,058 |
||
|
|
(99.9994%) |
|
(0.0006%) |
|
|
||||
|
|
|
|
|
|
|
|
|
||
|
2 |
(a) To re-elect Mr Simon To as a director. |
|
49,077,310 |
|
62,950 |
|
1,036,575 |
||
|
|
(99.8719%) |
|
(0.1281%) |
|
|
||||
|
|
|
|
|
|
|
|
|
||
|
|
(b) To re-elect Mr Christian Hogg as a director. |
|
50,155,427 |
|
21,250 |
|
158 |
||
|
|
(99.9576%) |
|
(0.0424%) |
|
|
||||
|
|
|
|
|
|
|
|
|
||
|
|
(c) To re-elect Mr Christian Salbaing as a director. |
|
50,155,397 |
|
21,280 |
|
158 |
||
|
|
(99.9576%) |
|
(0.0424%) |
|
|
||||
|
|
|
|
|
|
|
|
|
||
|
|
(d) To re-elect Ms Edith Shih as a director. |
|
50,155,647 |
|
21,030 |
|
158 |
||
|
|
(99.9581%) |
|
(0.0419%) |
|
|
||||
|
|
|
|
|
|
|
|
|
||
|
|
(e) To re-elect Mr Christopher Nash as a director. |
|
49,116,261 |
|
1,060,416 |
|
158 |
||
|
|
(97.8866%) |
|
(2.1134%) |
|
|
||||
|
|
|
|
|
|
|
|
|
||
|
|
(f) To re-elect Mr Michael Howell as a director. |
|
49,055,784 |
|
1,120,892 |
|
159 |
||
|
|
(97.7661%) |
|
(2.2339%) |
|
|
||||
|
|
|
|
|
|
|
|
|
||
|
|
(g) To re-elect Professor Christopher Huang as a director. |
|
49,116,211 |
|
1,060,466 |
|
158 |
||
|
|
(97.8865%) |
|
(2.1135%) |
|
|
||||
|
|
|
|
|
|
|
|
|
||
|
3 |
To re-appoint PricewaterhouseCoopers as the auditor of Chi-Med and authorise the board of directors to fix the auditor’s remuneration. |
|
50,111,239 |
|
44,588 |
|
21,008 |
||
|
|
(99.9111%) |
|
(0.0889%) |
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
4 |
Ordinary Resolution No. 4(A) |
: |
To grant a general mandate to the directors of Chi-Med to issue additional shares. |
|
50,174,133 |
|
2,371 |
|
331 |
|
|
(99.9953%) |
|
(0.0047%) |
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
Special Resolution No. 4(B) |
: |
To disapply pre-emption rights. |
|
47,883,975 |
|
2,253,552 |
|
39,108 |
|
|
(95.5053%) |
|
(4.4947%) |
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
Ordinary Resolution No. 4(C) |
: |
To grant a general mandate to the directors of Chi-Med to repurchase shares of Chi-Med. |
|
50,108,396 |
|
68,288 |
|
151 |
|
|
(99.8639%) |
|
(0.1361%) |
|
|
||||
* Percentages rounded to 4 decimal places
# A vote withheld is not a vote in law and is not counted in the calculation of the proportion of the votes for and against a resolution.
As at the date of the AGM, the number of issued shares of Chi-Med was 60,639,926, which was the total number of shares entitling the holders to attend and vote on the ordinary resolutions and special resolution proposed at the AGM.
Ends
|
Investor Inquiries |
|
|
Christian Hogg, CEO |
+852 2121 8200 |
|
International Media Inquiries |
|
|
Anthony Carlisle, Citigate Dewe Rogerson |
+44 7973 611 888 (Mobile) |
|
U.S. Based Media Inquiries |
|
|
Brad Miles, BMC Communications |
+1 (917) 570 7340 (Mobile) |
|
Susan Duffy, BMC Communications |
+1 (917) 499 8887 (Mobile) |
|
Investor Relations |
|
|
Jillian Connell, The Trout Group |
+1 (646) 378 2956 |
|
David Dible, Citigate Dewe Rogerson |
+44 20 7638 9571 |
|
Panmure Gordon (UK) Limited |
|
|
Richard Gray / Andrew Potts |
+44 (20) 7886 2500 |
Chi-Med is a China-based, globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.
Abstract (please download the poster for full details)
Authors: Evan Barry, Ryan Henry, Alexandra Borodovsky, Elizabeth Maloney, Brendon Ladd, Melanie Frigault, Michael Zinda, Edwin Clark, Alwin Schuller and Celina D’Cruz
Alterations in the MET oncogene occurs across a broad range of tumor indications. Amplification or mutations in MET lead to increased activity of downstream pathways including PI3K and MAPK, eventually resulting in tumor formation. Several small molecule inhibitors are currently in clinical trials, including the selective inhibitor Savolitinib (HMP-504, Volitinib, AZD6094), which shows single digit nanomolar activity in MET-amplified cell lines.
Newly emerging data suggest mutations in MET causing complete skipping of Exon 14 occur in approximately 4% of non-small cell lung cancer (NSCLC), and are more rare in other indications. Exon 14 harbors the CBL binding site (Y1003), which is critical for receptor degradation after binding of it’s ligand, HGF, and suppression of downstream signaling. Clinical trial results with less potent, pan RTK inhibitors Crizotinib (31nM GI50 vs 3nM for Savolitinib) and Cabozantinib show promising early results, but fall short in long term responses. Therefore, better therapies targeting MET are needed.
We utilized engineered, as well as endogenously expressing MET Ex14 mutant models to determine activity of Savolitinib. We found that Savolitinib potently inhibited phosho-MET in both model types. In addition, we found that savolitinib inhibited HGF-induced growth of the NSCLC model H596, which harbors loss of exon 14. In addition to the MET exon14 patient population, MET amplification also drives tumor formation in EGFR WT NSCLC. We previously presented EGFR activation as a resistance mechanism to Savolitinib in some clonal subpopulations. Here, we present an underlying mechanism of resistance found in all clones tested. We found that decoupling of MYC expression from MET activity was a hallmark of resistance. Overexpression of MYC in parental H1993 cells in a doxycycline-dependent manner resulted in resistance to Savolitinib. Parental as well as Savolitinib resistant H1993s depended on MYC expression, as knockdown resulted in loss of viability.
Together, this data demonstrates that Savolitinib is active against clinically relevant MET Ex14 mutations in addition to amplification, and that resistance ultimately may develop through decoupling MYC activity from MET signaling.
London: Wednesday, April 13, 2016: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) announces that the underwriters of its offering of American depositary shares (“ADSs”) on the Nasdaq Global Select Market (the “Offering”) have exercised their overallotment option. The underwriters elected to purchase an additional 660,000 ADSs at a price of US$13.50 per ADS, raising an additional US$8,910,000 in gross proceeds and bringing the total gross proceeds of the Offering to US$110,160,000, through the sale of an aggregate of 8,160,000 ADSs, each representing one-half of one ordinary share of Chi-Med. All of the ADSs in the Offering were sold by Chi-Med.
BofA Merrill Lynch and Deutsche Bank Securities (in alphabetical order) acted as joint global coordinators and joint bookrunners for the Offering. Stifel, Canaccord Genuity, Panmure Gordon & Co. and CITIC CLSA acted as co-managers for the Offering.
In connection with the Offering, a registration statement on Form F-1 (the “Form F-1 Registration Statement”) has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (“SEC”). The Offering was made only by means of a prospectus. Copies of the final prospectus related to the Offering may be accessed through the SEC’s website at www.sec.gov or obtained from (in alphabetical order): (i) BofA Merrill Lynch, Attn: Prospectus Department, 222 Broadway, New York, NY 10038, or by email at dg.prospectus_requests@baml.com, or (ii) Deutsche Bank Securities Inc., Attn: Prospectus Group, 60 Wall Street, New York, NY 10005, or by email at prospectus.cpdg@db.com.
This announcement does not constitute an offer to sell or the solicitation of an offer to buy ADSs or any other securities, nor shall there be any sale of ADSs in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Application has also been made for the 330,000 new ordinary shares issued by Chi-Med pursuant to the exercise of the overallotment option, represented by the 660,000 ADSs, to be admitted to trading on AIM, and it is expected that admission will become effective at 8:00 a.m. (GMT+1) on April 15, 2016. The 330,000 new ordinary shares issued by Chi-Med pursuant to the exercise of the overallotment option have been credited as fully paid and rank pari passu in all respects with the existing ordinary shares. As of the closing of the overallotment exercise, the issued share capital of Chi-Med is 60,613,118, and this figure may be used by shareholders as a denominator for the calculations by which they determine if they are required to notify their interest in, or change to their interest in, Chi-Med under the Disclosure and Transparency Rules, as incorporated into Chi-Med’s articles of association.
For illustrative purposes only, the 60,613,118 ordinary shares would be equivalent to 60,613,118 CREST depositary interests (each equating to one ordinary share) or, if the CREST depositary interests were converted in their entirety, equivalent to 121,226,236 ADSs (each equating to one-half of one ordinary share).
Ends
Chi-Med
Christian Hogg, CEO
+852 2121 8200
International Media Enquiries
Anthony Carlisle, Citigate Dewe Rogerson
+44 7973 611 888 (Mobile)
anthony.carlisle@cdrconsultancy.co.uk
U.S. Based Media Enquiries
Brad Miles, BMC Communications
+1 (917) 570 7340 (Mobile)
bmiles@bmccommunications.com
Susan Duffy, BMC Communications
+1 (917) 499 8887 (Mobile)
sduffy@bmccommunications.com
Investor Relations
Jillian Connell, The Trout Group
+1 (646) 378 2956
jconnell@troutgroup.com
David Dible, Citigate Dewe Rogerson
+44 20 7638 9571
+44 7967 566 919 (Mobile)
david.dible@citigatedr.co.uk
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts
+44 20 7886 2500
Chi-Med is a China-based, globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.
London: Tuesday, April 12, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated the first-in-human (“FIH”) Phase I clinical trial of HMPL-689 in Australia. HMPL-689 is a novel, highly selective and potent small molecule inhibitor targeting the delta isoform of the phosphatidylinositol-3-kinase, also known as PI3Kδ, a key component in the B-cell receptor signaling pathway. The first drug dose was administered on April 7, 2016.
The FIH trial aims to evaluate the safety, tolerability, and pharmacokinetics properties of HMPL-689. This randomized, double blind, placebo-controlled, dose-escalating Phase I study of HMPL-689 will be conducted in healthy adult volunteers. Following this FIH Phase I trial, HMP plans to investigate HMPL-689 in hematological malignancies. In pre-clinical studies, not only did HMPL-689 demonstrate a superior potency and better kinase selectivity as compared to drugs in the same class, but it also showed significant efficacy and a favorable safety profile. Additional details about this study may be found at clinicaltrials.gov, using identifier NCT02631642.
Ends
Chi-Med
Christian Hogg, CEO
+852 2121 8200
International Media Enquiries
Anthony Carlisle, Citigate Dewe Rogerson
+44 7973 611 888 (Mobile)
anthony.carlisle@cdrconsultancy.co.uk
U.S. Based Media Enquiries
Brad Miles, BMC Communications
+1 (917) 570 7340 (Mobile)
bmiles@bmccommunications.com
Susan Duffy, BMC Communications
+1 (917) 499 8887 (Mobile)
sduffy@bmccommunications.com
Investor Relations
Jillian Connell, The Trout Group
+1 (646) 378 2956
jconnell@troutgroup.com
David Dible, Citigate Dewe Rogerson
+44 20 7638 9571
+44 7967 566 919 (Mobile)
david.dible@citigatedr.co.uk
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts
+44 20 7886 2500
As one of the major cellular components of the immune system, B-cells play pivotal roles in several immune system related diseases, such as autoimmune diseases including rheumatoid arthritis, systemic lupus erythematosus and allergy, as well as hematological cancers (i.e. B-cell malignancies), including lymphoma and leukemia. Targeted B-cell receptor signaling therapies, including monoclonal antibodies and small molecules, have been proven to be clinically effective for the treatment of rheumatoid arthritis as well as B-cell malignancies, leading to scientific and commercial success.
PI3Kδ is a key kinase involved in the B-cell signaling pathway and serves as an attractive target for novel therapies in hematology and immunology.
Hematological cancers are classified as leukemia (affecting blood and bone marrow), lymphoma (affecting the lymphatic system) and myeloma (affecting bone marrow). According to Frost & Sullivan, there were approximately 983,000 new cases of hematological cancers worldwide in 2015, which is expected to increase to approximately 1.1 million new cases annually by 2020. The global market for hematological cancer treatments is projected to grow from approximately $20.4 billion in 2015 to $25.7 billion by 2020. Treatment of hematological cancers is determined on a case-by-case basis and primarily involves chemotherapy, radiation, targeted therapy and/or stem cell transplantation and, more recently, immunotherapy and gene therapy.
HMP is a novel drug R&D company focusing on discovering, developing and commercializing innovative therapeutics in oncology and autoimmune diseases. With a team of around 290 scientists and staff, its pipeline is comprised of novel oral compounds for cancer and inflammation in development in North America, Europe, Australia and Greater China. HMP is a subsidiary of Chi-Med and a part of Chi-Med’s Innovation Platform. For more information, please visit: www.hmplglobal.com.
Chi-Med is a China-based, globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.
This announcement contains forward-looking statements that reflect Chi-Med’s current expectations regarding future events, including its plans to initiate clinical studies for its drug candidates in the targeted indications, its expectations as to whether such studies would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Forward-looking statements involve
risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding enrolment rates, timing and availability of subjects meeting a study’s inclusion and exclusion criteria, changes to clinical protocols or regulatory requirements, unexpected adverse events or safety issues, the ability of a drug candidate to meet the primary or secondary endpoint of a study, the ability of a drug candidate to obtain regulatory approval in different jurisdictions, the ability of a drug candidate to gain commercial acceptance after obtaining regulatory approval, the potential market of a drug candidate for a targeted indication and the sufficiency of funding. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Chi-Med undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.
Dr. John Newman
+1 212 389 8042
JNewman@canaccordgenuity.com
Tony Ren
+852 2600 7549
tony.ren@clsa.com
Cyrus Ng
+852 2203 6208
cyrus-a.ng@db.com
Dr. Susie Jana
+44 20 3077 5700
healthcare@edisongroup.com
Junjie Huang
+86 21 6081 3859
junjie.huang@hsbcqh.com.cn
Tony Ren
tony.ren@macquarie.com
Candyce Gao
+852 3922 5964
candyce.gao@macquarie.com
Sean Wu
+852 3963 0755
sean.wu@morganstanley.com
Laurence Tam
+852 2239 1753
laurence.tam@morganstanley.com
Dr. Mike Mitchell
+44 20 7886 2761
mike.mitchell@panmure.com
Franc Gregori
+44 20 3637 5041
fgregori@trinitydelta.org
Lala Gregorek
+44 20 3637 5043
lgregorek@trinitydelta.org
To attend and vote at the AGM, all transfers must be lodged with the share registrar no later than 4:00 pm British Standard Time (11:00 am Eastern Standard Time) on Monday, April 25, 2016.
Las Vegas, NV, United States
Boston, MA, United States